ClinicalTrials.gg
CompletedNCT03462017Updated Apr 25, 2022

Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus

A Phase 1 interventional study of SAR247799 and Placebo in Microvascular Coronary Artery Disease, sponsored by Sanofi. Completed at 2 sites in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.

Enrollment
206th of 248
54 · median 265
Started
2018
with 20 others
Phase 1
9 of 365
1 open now
Registered
250th of 365
by date

Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 206th largest by enrollment of the 248 interventional ones that give a count, is one of 21 that started in 2018, is one of 9 in phase 1, and was the 250th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Coronary Artery Disease with a site in Germany, or all of them as a file.
02

Study summary

Primary Objective:

To assess the pharmacodynamic effects of SAR247799 on macrovascular endothelial function of the brachial artery using flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM).

Secondary Objective:

  • To assess the pharmacodynamic effects of SAR247799 on microvascular endothelial function using laser Doppler perfusion monitoring in patients with T2DM.
  • To assess the safety profile of SAR247799 in patients with T2DM.
  • To assess the plasma pharmacokinetic profile of SAR247799 in patients with T2DM.
Read the detailed description

Study duration per patient is approximately 10 weeks including a 4-week treatment period.

03

Conditions studied

  • Microvascular Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female stable Type 2 diabetes mellitus (T2DM) patients.
  • between 18 and 35 kg/m\^2.
  • Stable T2DM patients, but otherwise healthy as assessed by a clinical and laboratory assessments and detailed medical history.
  • Diagnosis of T2DM for at least 6 months at the time of the screening visit.
  • Glycosylated () \< 8.5%.
  • estimated ˃60 mL/min/1.73 m\^2.
  • Flow-mediated dilatation (FMD) ≤7% at screening.
  • Treatment of T2DM with lifestyle interventions or stable oral antidiabetic treatment for at least 3 months prior to inclusion.
  • No abnormality detected in cardiac echography, as assessed by certified Cardiologist, performed at screening.

Exclusion criteria

Exclusion criteria:

  • Any history or presence of or symptomatic gastrointestinal, hepatic, metabolic (except stable T2DM and controlled dyslipidemia), hematological, osteomuscular, articular, psychiatric, systemic, gynecologic (if female), or infectious disease, or ongoing cancer (including basal cell skin carcinoma), or signs of acute illness which as judged by the Investigator, may affect the patient's participation in or the outcome of this study.
  • Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥30 mmHg within 3 minutes when changing from 10 min supine to standing position, at screening.
  • History of symptomatic bradycardia, fainting, collapse, syncope, or vasovagal reactions in the last 6 months.
  • Presence or history of drug and/or allergy to any ingredients of the product and/or non-investigational product diagnosed and treated by a physician.
  • Any subject who cannot be treated with sildenafil because of conditions mentioned in the , warning and precautions sections of sildenafil product information notably subjects with anatomical deformity of the penis.
  • Loss of vision due to non-arteritic, neuro-optic, anterior ischemia assessed in ophtalmologic examination at screening.
  • If female, pregnancy (defined as positive β-human chorionic gonadotropin blood and urine test), breast-feeding.
  • Generally any medication which has a potential to interfere with the safety, pharmacokinetics of SAR247799 and sildenafil, or with study measurements is not allowed, and in particular:
  • Nitrates, all calcium channel blockers, phosphodiesterase type 5 inhibitors (except investigational medicinal product [IMP]), guanylate cyclase stimulators use or anticipated during the study;
  • Beta-blockers;
  • Glucagon-like peptide-1 agonists;
  • Insulins (all types);
  • Anticoagulants, antithrombotics except aspirin;
  • Any drugs which decrease heart rate;
  • Antiarrhythmics;
  • Digoxin;
  • Cholinergic agents eg pilocarpine or cholinesterase inhibitors eg neostigmine, guanidine;
  • Recent (≤3 months) use of systemic or therapy;
  • Any inactivated vaccination (eg, seasonal influenza) during study treatment, any attenuated vaccination within 2 months before inclusion, and any biologics (antibody or its derivatives) given within 4 months before inclusion;
  • Any consumption of citrus fruits (grapefruit, orange, etc) or their juices within 3 days before inclusion as weak inhibitor of gut wall metabolism.
  • Any severe dyslipidemia with fasting triglycerides > 450 mg/dL.
  • Any hyperosmolar hyperglycemic episode with severe neurological symptoms (eg, coma, aphasia) in the last 3 months before screening.
  • Weight change of ≥5 kg during the last 2 months prior to screening.
  • History or presence of clinically relevant or symptomatic pulmonary disease, such as asthma, , pulmonary embolism, pulmonary fibrosis, pulmonary hypertension which as judged by the Investigator, may affect the patient's participation in or the outcome of this study.
  • Cardiovascular history such as:
  • History or presence of a clinically relevant or symptomatic cardiovascular disease such as acute coronary syndrome (ACS), stroke, transient ischemic accident (), obstructive or congestive heart failure, or structural heart disease (e.g., valvular disease) which as judged by the Investigator, may affect the patient's participation in or the outcome of this study.
  • History of elective percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the past 6 months.
  • History of clinically relevant or symptomatic cardiac arrhythmia such as sustained ventricular arrhythmia, non-fixed supra-ventricular arrhythmia which as judged by the Investigator, may affect the patient's participation in or the outcome of this study or which occurred within the past 6 months
  • History of clinically relevant or symptomatic cardiac conduction abnormalities (any type of atrioventricular (AV) block, sick sinus syndrome, sinus node disease).
  • Patients with a pacemaker or implantable cardioverter defibrillator.
  • Known history of disorders.
  • Any severe viral, systemic, fungal, bacterial or protozoal infection within the past 6 months or chronic severe infection (hepatitis, infection, tuberculosis).
  • Presence of macular edema at fundus examination performed within 6 months before the first study drug administration.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    SAR247799

    SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design

    Drug: SAR247799 · Drug: Acetylcholine

  • Placebo comparator
    Placebo

    Identical matching placebo for SAR247799 and for sildenafil once daily in the morning under fasted condition for 28 days

    Drug: Placebo · Drug: Acetylcholine

  • Active comparator
    Sildenafil

    Sildenafil once daily in the morning under fasted condition for 28 days

    Drug: Sildenafil · Drug: Acetylcholine

Interventions

  • DrugSAR247799

    Pharmaceutical form:Capsule Route of administration: Oral

  • DrugPlacebo

    Pharmaceutical form:Capsule Route of administration: Oral

  • Pharmaceutical form:Encapsulated tablet Route of administration: Oral

  • Pharmaceutical form:Solution Route of administration: Transdermal

06

What researchers measure

Primary outcomes

  1. Change in Flow Mediated Dilation (FMD)

    Absolute change from baseline in the % FMD index of the brachial artery

    Time frame: Baseline to Days 14, 21, 28, 35, and 42

Secondary outcomes

  1. Microvascular reactivity

    Change from baseline in peak flow induced by acetylcholine iontophoresis measured using Laser Doppler perfusion monitoring

    Time frame: Baseline to Days 14, 21, 28, 35, and 42

  2. Number of adverse events

    Number of participants with adverse events

    Time frame: Up to Day 42

  3. Assessment of pharmacokinetic (PK) parameter: Cmax

    Cmax: Maximum plasma concentration observed

    Time frame: Days 1, 2, 3, 7, and 14

  4. Assessment of PK parameter: Ctrough

    Ctrough: Plasma concentration observed just before treatment administration during repeated dosing

    Time frame: Days 1, 2, 3, 7, and 14

  5. Assessment of PK parameter: tmax

    tmax: Time to reach Cmax

    Time frame: Days 1, 2, 3, 7, and 14

  6. Assessment of PK parameter: AUC0-24

    AUC0-24: Area under the plasma concentration versus time curve over the dosing interval (24h)

    Time frame: Days 1, 2, 3, 7, and 14

07

Study locations

2 sites
  • Investigational Site Number 2760002
    Mainz, 55116, Germany
  • Investigational Site Number 2760001
    Neuss, 41460, Germany
08

References and documents

Publications

  • Bergougnan L, Andersen G, Plum-Morschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. Br J Clin Pharmacol. 2021 May;87(5):2303-2320. doi: 10.1111/bcp.14632. Epub 2020 Nov 26. PubMed 33125753 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Dec 2018, 9 months.

Of 34 phase 1 interventional studies under Coronary Artery Disease, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 9 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2018
First posted
Mar 12, 2018
StartActual
Mar 7, 2018
Primary completionActual
Dec 22, 2018
CompletionActual
Dec 22, 2018
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03462017
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Mar 7, 2018
Primary completion
Dec 22, 2018
Completion
Dec 22, 2018
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion